The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: A systematic review and meta-analysis

Current Neuropharmacology

Volumn 12, Issue 3, 2014, Pages 256-268

  Kawalec, Paweł ^a   Mikrut, Alicja ^c   Wiśniewska, Natalia ^c   Pilc, Andrzej ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c NONE

Author keywords

Autoimmune disorder; Dimethyl fumarate; Disease modifying therapies; Relapsing remitting multiple sclerosis

Indexed keywords

FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; PLACEBO; TERIFLUNOMIDE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIARRHEA; DISABILITY SEVERITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FLUSHING; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; JADAD QUALITY SCORE; META ANALYSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SCORING SYSTEM; SKIN DISEASE; SYSTEMATIC REVIEW; UPPER ABDOMINAL PAIN;

EID: 84914173010     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X12666140115214801     Document Type: Article

References (43)

1. Loma, I.; Heyman, R. Multiple sclerosis: pathogenesis and treatment. Curr. Neuropharmacol., 2011, 9(3), 409-416. http://dx.doi.org/10. 2174/157015911796557911
2. Alonso, A.; Hernan, M.A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology, 2008, 71, 129-135. http://dx.doi.org/10.1212/01.wnl.0000316802.35974.34
3. Limmroth, V. Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS. Nat. Rev. Neurol., 2013, 9, 8-10. http://dx. doi.org/10.1038/nrneurol.2012.231
4. Tullman, M. A Review of current and emerging therapeutic strategies in multiple sclerosis. Am. J. Manag Care, 2013, 19, 21- 27. PMID: 23544717 [PubMed - in process]
5. Fox, E.J.; Rhoades, R.W. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr. Opin. Neurol., 2012, 25, Suppl, 11-19. http://dx.doi.org/10.1097/01.wco. 0000413320.94715.e9
6. Killestein, J.; Rudick, R.A.; Polman, C.H. Oral treatment for multiple sclerosis. Lancet Neurol., 2011, 10, 1026-1034. http://dx. doi.org/10.1016/S1474-4422(11)70228-9
7. Nicholas, R.; Giannetti, P.; Alsanousi, A.; Friede, T.; Muraro, P.A. Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel. Ther., 2011, 5, 255-274. http://dx.doi.org/10.2147/DDDT.S10498
8. Oh, J.; O'Connor, P.W. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs, 2013, 27(8), 591-609. http://dx.doi.org/10.1007/s40263-013-0080-z
9. Stangel, M.; Linker, R.A. Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. Expert Rev. Clin. Pharmacol., 2013, 6(4), 355-362. http://dx.doi.org/10.1586/17512433.2013. 811826
10. Moharregh-Khiabani, D.; Linker, R.A.; Gold, R.; Stangel, M. Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr. Neuropharmacol., 2009, 7(1), 60-64. http://dx.doi. org/10.2174/157015909787602788
11. Polman, C.H.; Reingold, S.C.; Edan, G.; Filippi, M.; Hartung, H.P.; Kappos, L.; Lublin, F.D.; Metz, L.M.; McFarland, H.F.; O'Connor, P.W.; Sandberg-Wollheim, M.; Thompson, A.J.; Weinshenker, B.G.; Wolinsky, J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol., 2005, 58(6), 840-846. http://dx.doi.org/10.1002/ana.20703
12. Jadad, A.R.; Moore, R.A.; Carroll, D.; Jenkinson, C.; Reynolds, D.J.; Gavaghan, D.J.; McQuay, H.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials, 1996, 17(1), 1-12. http://dx.doi.org/10.1016/0197-2456(95) 00134-4
13. Higgins, J.P.T.; Green, S. (editors) Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. Cochrane Collaboration and John Wiley, 2011. Available from: www.cochrane-handbook.org. (accessed 3 Nov 2013). http://dx.doi.org/10.1002/jrsm.38
14. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA statement. PLoS Med., 2009, 151, 264-649. http://dx.doi. org/10.7326/0003-4819-151-4-200908180-00135
15. Gold, R.; Kappos, L.; Arnold, D.L.; Giovannoni, G.; Selmaj, K.; Tornatore, C.; Sweetser, M.T.; Yang M.; Sheikh, S.I.; Dawson, K.T.; DEFINE Study Investigators. DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med., 2012, 367, 1098-1107. http://dx.doi.org/10.1056/NEJMoa1114287
16. Bar-Or, A.; Gold, R.; Kappos, L.; Arnold D.L.; Giovannoni, G.; Selmaj, K.; O'Gorman, J.; Stephan. M.; Dawson K.T. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsingremitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol., 2013, 260(9), 2297-2305. http://dx.doi.org/10.1007/ s00415-013-6954-7
17. Kappos, L.; Gold, R.; Arnold, D.L.; Bar-Or A.; Giovannoni, G.; Selmaj, K.; Sarda S.P.; Agarwal, S.; Zhang, A.; Sheikh, S.I.; Seidman, E.; Dawson, K.T. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study. Mult. Scler., 2013, 22. [Epub ahead of print]. http://dx.doi.org/10.1177/1352458513507817
18. Kappos L.; Gold, R.; Arnold D.L.; Bar-Or, A.; Giovannoni, G.; Selmaj, K.; Sarda, S.P.; Agarwal, S.; Zhang, A.; Sheikh, S.I.; Dawson K.T. Effects of BG-12 on quality of life in relapsingremitting multiple sclerosis: Findings from the phase 3 define study. Value in Health, 2012, 15(7), A557. http://dx.doi.org/10.1016/ j.jval.2012.08.1987
19. Bar-Or, A.; Gold, R.; Kappos, L., Arnold, D.; Giovannoni, G.; Selmaj, K.; O'Gorman, J; Stephan, M.; Dawson, K. Effect of BG- 12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: Findings from the DEFINE study. Eur. J. Neurol., 2012, 19, SUPPL.1 (356). 10.1212/ WNL.78.1
20. Fox, R.J.; Miller, D.H.; Phillips, J.T.; Hutchinson, M.; Havrdova, E.; Kita, M.; Yang, M.; Raghupathi, K.; Novas, M.; Sweetser, MT.; Viglietta, V.; Dawson, K.T. CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med., 2012, 367, 1087-1097. http://dx.doi.org/10.1056/NEJMoa1206328
21. Hutchinson, M.; Fox, R.J.; Miller, D.H.; Phillips J.T.; Phillips, J.T.; Kita, M.; Havrdova, E.; O'Gorman, J.; Zhang, R.; Novas, M.; Viglietta, V.; Dawson K.T. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J. Neurol., 2013, 260(9), 2286-2296. http://dx.doi.org/10.1007/s00415-013-6968-1
22. Kita, M.; Fox, R.J.; Phillips, J.T.; Hutchinson, M.; Havrdova, E.; Sarda, S.P.; Agarwal, S.; Kong, J.; Zhang A.; Viglietta, V.; Sheikh, S.I.; Seidman, E.; Dawson, K.T. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult. Scler., 2013, 22. [Epub ahead of print]. http://dx.doi.org/10.1177/1352458513507818
23. Kita, M.; Fox, R.J.; Phillips, J.T.; Hutchinson, M.; Havrdova, E.; Sarda, S.P.; Kong, J.; Viglietta, V.; Sheikh, S.I.; Dawson, K.T. Effects of BG-12 on quality of life in relapsing-remitting multiple sclerosis: Findings from the phase 3 confirm study. Value Health, 2012, 15(7), A556. http://dx.doi.org/10.1016/j.jval.2012.08.1982
24. Havrdova, E.; Miller, D.; Fox, R.J.; Phillips, J.T.; Kita, M.; Hutchinson, M.; MacManus, D.; Yousry, T.; Yang, M.; Zhang, R.; Novas, M.; Viglietta, V.; Dawson, K.T. Clinical and neuroimaging outcomes with BG-12 treatment in CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis), a multicenter, randomized, placebocontrolled, phase-3 study. Eur. J. Neurol., 2012, 19, SUPPL. 1 (87). Print ISSN: 1351-5101 http:// discovery.ucl.ac.uk/1372064/
25. Bar-Or, A.; Fox, R.J.; Gold, R.; Miller, D.H.; Arnold, D.L.; O'Gorman, J.; Yang, M.; Sheikh, S.I.; Viglietta, V.; Dawson, K.T.; Hutchinson, M. Clinical and neuroradiological effect of BG - 12 (dimethyl fumarate) in subgroups of patients with relapsingremitting multiple sclerosis (RRMS): An integrated analysis of the phase 3 define and confirm studies. Value Health, 2013, 16(3), A102.PMMID: 23693184
26. Bar-Or, A, Gold R, Fox RJ, Havrdova, E.; Selmaj, K.; Kurukulasuriya, N.C.; Yang, M.; Raghupathi, K.; Novas, M.; Sweetser, M.T.; Viglietta, V.; Dawson, K.T.; Phillips, J.T. Clinical efficacy and safety of oral BG-12 (dimethyl fumarate) in relapsingremitting multiple sclerosis (RRMS): An integrated analysis of the phase 3 define and confirm studies. Mult. Scler., 2012, 18(12), 1828. 10.1177/1352458512466528
27. Bar-Or, A.; Arnold, D.L.; Gold, R.; Fox, R.J.; MacManus, D.G.; Yousry, T.; Kurukulasuriya, N.C.; Zhang, R.; Viglietta, V.; Stephan, M.; Dawson, K.T.; Miller, D.H. Effects of oral BG-12 (Dimethyl Fumarate) on magnetic resonance imaging (Mri) outcomes in relapsing-remitting multiple sclerosis (RRMS): An integrated analysis of the phase 3 define and confirm studies. Mult. Scler., 2012, 18(12), 1836. 10.1177/1352458512466528
28. Giovannoni, G.; Gold, R.; Fox, R.J.; Kita, M.; Yang, M.; Zhang, R.; Dawson, K.T.; Viglietta, V.; Sheikh, S.I.; Havrdova, E. An integrated analysis of relapses requiring intravenous steroid use and multiple sclerosis (MS)-related hospitalizations from the BG-12 (dimethyl fumarate) phase 3 define and confirm studies. Value Health, 2013, 16(3), A101-A102. http://dx.doi.org/10.1016/j.jval. 2013.03.481_
29. Bar-Or, A.; Selmaj, K.; Gold, R.; Fox, R.J.; Havrdova, E.; Kurukulasuriya, N.C.; Pace, A.; Novas, M.; Meltzer, L.; Hotermans, C.; Dawson, K.T.; Phillips, J.T. Gastrointestinal tolerability events in relapsing-remitting multiple sclerosis (RRMS) patients treated with oral BG-12 (Dimethyl Fumarate) in define and confirm. Mult. Scler., 2012, 18(12), 1840-1841. 10.1177/ 1352458512466528_
30. Havrdova, E.; Gold, R.; Fox, R.J.; Kappos, L.; Kita, M.; Sarda, S.P.; Yang, M.; Zhang, R.; Dawson, K.T.; Viglietta, V.; Sheikh, S.I.; Giovannoni, G. Relapses requiring intravenous steroids and multiple sclerosis related hospitalizations: Findings from the phase 3 define and confirm studies. Value Health, 2012, 15(7), A546. http://dx.doi.org/10.1016/j.jval.2012.08.1927_
31. Havrdova, E.; Phillips, J.T.; Selmaj, K.; Gold, R.; Fox, R.J.; Giovannoni, G.; Pace, A.; Novas, M.; Kurukulasuriya, N.C.; Hotermans, C.; Meltzer, L.; Dawson, K.T. Gastrointestinal tolerability events in relapsing- remitting multiple sclerosis patients treated with BG-12 (dimethyl fumarate): Integrated analysis of DEFINE and CONFIRM. J. Neurol. Sci., 2013, 333, SUPPL. 1, 368-369. http://dx.doi.org/10.1016/j.jns.2013.07.1347
32. Havrdova, E.; Hutchinson, M.; Kurukulasuriya, N.C.; Raghupathi, K.; Sweetser, M.T.; Dawson, K.T.; Gold, R. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med., 2012,367,1098-107
33. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J .Med., 2012, 367, 1087-97. Expert Opin. Pharmacother., 2013, 14(15), 2145-56. http://dx.doi.org/10.1517/14656566.2013.826190
34. Hutchinson, M.; Fox, R.J.; Havrdova, E.; Kurukulasuriya, N.C.; Sarda, S.P.; Agarwa, S.; Siddiqui, M.K.; Taneja, A.; Deniz, B. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing- remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr. Med. Res. Opin., 2013, Nov 26 [Epub ahead of print]. http://www.neurology.org/cgi/content/meeting_ abstract/80/1_MeetingAbstracts/P07.127
35. Gold, R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs, 2011, 25, 37-52. http://dx.doi.org/10.2165/11539820-000000000-00000
36. Castro-Borrero, W.; Graves, D.; Frohman, T.C.; Flores, A.B.; Hardeman, P.; Logan, D.; Orchard, M.; Greenberg, B.; Frohman, E.M. Current and emerging therapies in multiple sclerosis: A systematic review. Ther. Adv. Neurol. Disord., 2012, 5(4), 205- 220. http://dx.doi.org/10.1177/1756285612450936
37. Polman, C.H.; Reingold, S.C.; Barkhof, F.; Calabresi, P.A.; Clanet, M.; Cohen, J.A.; Cutter, G.R.; Freedman M.S.; Kappos, L.; Lublin, F.D.; McFarland, H.F.; Metz, L.M.; Miller, A.E.; Montalban, X.; O'Connor P.W.; Panitch, H.; Richert, J.R.; Petkau, J.; Schwid, S.R.; Sormani, M.P.; Thompson, A.J.; Weinshenker, B.G.; Wolinsky, J.S. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology, 2008, 70, 1134-1140. http://dx.doi.org/ 10.1212/01.wnl.0000306410.84794.4d
38. Schimrigk, S.; Brune, N,; Hellwig, K.; Lukas, C.; Bellenberg, B.; Rieks, M.; Hoffmann, V.; Pohlau, D.; Przuntek, H. Oral fumaric acid esters for the treatment of active multiple sclerosis: an openlabel, baseline-controlled pilot study. Eur. J. Neurol., 2006, 13(6), 604-610. http://dx.doi.org/10.1111/j.1468-1331.2006.01292.x
39. Kappos, L.; Gold, R.; Miller, D.H.; Havrdova, E.; Limmroth, V.; Polman, C.H.; Schmierer, K.; Yousry, T.A.; Yang, M.; Eraksoy, M.; Meluzinova, E.; Rektor, I.; Dawson, K.T.; Sandrock, A.W.; O'Neill, G.N.; BG-12 Phase IIb Study Investigators. BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, 2008, 372, 1463-1472. http://dx.doi.org/10.1016/S0140- 6736(08)61619-0
40. Kappos, L.; Gold, R.; Miller, D.H.; MacManus, D.G.; Havrdova, E.; Limmroth, V.; Polman, C.H.; Schmierer, K.; Yousry, T.A.; Eraksoy, M.; Meluzinova, E.; Dufek, M.; Yang, M.; Dawson, K.; O'Neill G.N. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult. Scler., 2012, 18 (3), 314- 321. http://dx.doi.org/10.1177/1352458511421054
41. MacManus, D.G.; Miller, D.H.; Kappos, L.; Gold, R.; Havrdova, E.; Limmroth, V.; Polman, C.H.; Schmierer, K.; Yousry, T.A.; Eraksoy, M.; Meluzinova, E.; Dufek, M.; Yang, M.; O'Neill, G.N.; Dawson, K. BG - 12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol., 2011, 258(3), 449-456. http://dx.doi.org/10.1007/s00415- 010-5777-z
42. Selmaj, K.; Phillips, J.T.; Fox, R.J.; Raghupathi, K.; Yuan, H.; Novas, M.; Sweetser, M.T.; Kurukulasuriya N.C.; Viglietta, V.; Dawson, K.T.; Gold, R. Safety and tolerability of BG-12 (dimethyl fumarate) in relapsing- remitting multiple sclerosis: Interim results from the endorse extension study. J. Neurol. Sci., 2013, 333, SUPPL. 1, 367-368. http://dx.doi.org/10.1016/j.jns.2013.07.1344
43. Song, F.; Altman, D.G.; Glenny, A.M.; Deeks, J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ, 2003, 326, 472. PMID: 1260994